2 results
Approved WMOCompleted
Part A - CX-2009 Monotherapy: Every 21-Day Dosing RegimenThe primary objective of Part A is to determine the safety profile of CX-2009, the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the dose-limiting toxicities(DLTs) of CX-…
Approved WMOCompleted
The objective of this study is to determine the safe and efficacious dose required to eradicate LGD or HGD in BE, or residual BE after endoscopic removal of early cancer (*therapeutic dose*), using the C2 CryoBalloon 180 Ablation System. *Dose* is…